-
Publication Venue For
-
A current and future outlook on upcoming technologies in remote monitoring of patients with heart failure.
2020
-
Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium.
2020
-
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials.
2020
-
Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the RELAX-AHF-2 study.
2020
-
Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan.
2020
-
All rise! Orthostatic hypotension in heart failure. Letter regarding the article 'Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients'..
22:1741.
2020
-
Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial..
22:1649-1658.
2020
-
Regional adiposity and heart failure with preserved ejection fraction..
22:1540-1550.
2020
-
Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial..
22:1451-1461.
2020
-
Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial.
2020
-
Hospitalizations for heart failure during the COVID-19 pandemic: making sense of the known knowns, known unknowns, and unknown unknowns.
2020
-
Patient-reported outcomes for heart failure with preserved ejection fraction: conducting quality studies on quality of life..
22:1019-1021.
2020
-
Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity..
22:1009-1018.
2020
-
The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF..
22:1022-1031.
2020
-
Trends in prevalence of comorbidities in heart failure clinical trials..
22:1032-1042.
2020
-
Depression and heart failure: the lonely comorbidity.
2020
-
The real world of de novo heart failure: the next frontier for heart failure clinical trials?
2020
-
One-year mortality after implantable cardioverter-defibrillator placement within the Veterans Affairs Health System..
22:859-867.
2020
-
Association between body surface area and prescribed doses of guideline-directed medications among international patients with heart failure and reduced ejection fraction..
22:754-758.
2020
-
Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission..
22:683-691.
2020
-
Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX-AHF-2 trial..
22:726-738.
2020
-
Diagnosing heart failure with preserved ejection fraction in 2019: the search for a gold standard..
22:422-424.
2020
-
Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis..
22:472-485.
2020
-
Effects of vericiguat in heart failure with reduced ejection fraction: do not forget sST2. Reply.
2020
-
Association between beta-blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score-matched analysis from the Swedish Heart Failure Registry..
22:103-112.
2020
-
Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial..
22:164-167.
2020
-
Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial..
21:1596-1604.
2019
-
Heart failure treatment and the art of medical decision making..
21:1510-1514.
2019
-
Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial..
21:1561-1570.
2019
-
Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial..
21:1472-1476.
2019
-
Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial..
21:1426-1433.
2019
-
Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations?.
21:1398-1401.
2019
-
Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial..
21:1270-1278.
2019
-
Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial..
21:1279-1287.
2019
-
In-hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time..
21:1008-1011.
2019
-
Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction..
21:974-984.
2019
-
Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure..
21:1022-1031.
2019
-
Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score..
21:770-778.
2019
-
Erratum to 'The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions' [Eur J Heart Fail 2018;20:963-972]..
21:819.
2019
-
Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges..
21:286-296.
2019
-
Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care..
21:121-124.
2019
-
Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION..
21:63-70.
2019
-
Impact of exercise-based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta-analysis of randomised trials..
20:1735-1743.
2018
-
Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial..
20:1760-1763.
2018
-
Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction..
20:1601-1610.
2018
-
Nomenclature in heart failure: a call for objective, reproducible, and biologically-driven terminology..
20:1379-1381.
2018
-
Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-HF registry..
20:1281-1289.
2018
-
Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study..
20:1257-1266.
2018
-
Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum..
20:1230-1239.
2018
-
Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy..
20:1227-1229.
2018
-
Early versus late readmission during the vulnerable phase following hospitalization for heart failure: reply..
20:1166.
2018
-
Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years..
20:1068-1071.
2018
-
Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes..
20:1031-1038.
2018
-
The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions..
20:963-972.
2018
-
Can walking patients with heart failure and preserved ejection fraction tell us who should walk also to the catheterization laboratory or just walk home?.
20:723-724.
2018
-
Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial..
20:677-686.
2018
-
Predictors and outcomes of heart failure with mid-range ejection fraction..
20:651-659.
2018
-
Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure..
20:504-510.
2018
-
Percutaneous edge-to-edge leaflet repair: a solution to the risk-treatment paradox of mitral regurgitation complicated by pulmonary hypertension?.
20:595-597.
2018
-
Potential advantages of torsemide in patients with heart failure: more than just a 'water pill'?.
20:471-473.
2018
-
Sudden cardiac death following admission for acute heart failure: adding insult to injury..
20:533-535.
2018
-
Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF..
20:304-314.
2018
-
Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial..
20:281-291.
2018
-
Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality..
20:295-303.
2018
-
Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe?.
20:317-322.
2018
-
Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study..
19:1520-1529.
2017
-
The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors..
19:1390-1400.
2017
-
A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure..
19:1310-1320.
2017
-
Protein turnover in the failing heart: an ever-changing landscape..
19:1218-1221.
2017
-
Improving heart failure health: is there a secret Swedish sauce?.
19:1117-1118.
2017
-
A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial..
19:1001-1010.
2017
-
Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?.
19:974-986.
2017
-
Finding the road to recovery: therapeutic and clinical trial implications of dysfunctional viable myocardium in heart failure with reduced ejection fraction..
19:870-872.
2017
-
Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS)..
19:739-747.
2017
-
Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure..
19:728-738.
2017
-
Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study..
19:800-809.
2017
-
Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes..
19:595-602.
2017
-
Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure..
19:673-681.
2017
-
Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial..
19:552-562.
2017
-
Carotid body resection for sympathetic modulation in systolic heart failure: results from first-in-man study..
19:391-400.
2017
-
Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial..
19:241-249.
2017
-
Diabetes and heart failure in the crosshairs: where is the target?.
19:66-68.
2017
-
Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme..
18:1508-1517.
2016
-
Biomarker-based risk prediction in the community..
18:1342-1350.
2016
-
Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis..
18:1238-1243.
2016
-
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment..
18:1162-1171.
2016
-
Targeting the vulnerable phase of heart failure: initiate novel therapies in stable patients prior to hospitalization..
18:1190-1192.
2016
-
Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality..
18:1041-1050.
2016
-
A Gordian knot: disentangling comorbidities in heart failure..
18:759-761.
2016
-
Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study..
18:830-839.
2016
-
Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials..
18:684-692.
2016
-
Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome..
18:641-649.
2016
-
Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF..
18:424-432.
2016
-
Signature of circulating microRNAs in patients with acute heart failure..
18:414-423.
2016
-
Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy..
18:290-297.
2016
-
Optimizing clinical use of biomarkers in high-risk acute heart failure patients..
18:269-280.
2016
-
Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study..
17:1262-1270.
2015
-
Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials..
17:1252-1261.
2015
-
Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study..
17:1133-1143.
2015
-
In-hospital worsening heart failure..
17:1104-1113.
2015
-
Insulin resistance in heart failure: widening the divide between reduced and preserved ejection fraction?.
17:991-993.
2015
-
Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial..
17:1022-1031.
2015
-
Reclassifying heart failure: time for disruptive innovation?.
17:879-880.
2015
-
Same protocol, different continents, different patients: should we continue to conduct global heart failure trials?.
17:875-878.
2015
-
Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) trial..
17:725-734.
2015
-
Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial..
17:697-706.
2015
-
Global variation in clinical profile, management, and post-discharge outcomes among patients hospitalized for worsening chronic heart failure: findings from the ASTRONAUT trial..
17:591-600.
2015
-
REPORT-HF: the unique blend of global heart failure registry and longitudinal cohort study..
17:472-474.
2015
-
Impact of surgical ventricular reconstruction on sphericity index in patients with ischaemic cardiomyopathy: follow-up from the STICH trial..
17:453-463.
2015
-
Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT)..
17:301-312.
2015
-
Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction..
17:135-143.
2015
-
Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme..
17:196-204.
2015
-
Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial..
17:109-118.
2015
-
Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial..
17:98-108.
2015
-
Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study..
16:1362-1371.
2014
-
Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF..
16:1230-1240.
2014
-
Persistent angina pectoris in ischaemic cardiomyopathy: increased rehospitalization and major adverse cardiac events..
16:854-860.
2014
-
International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial..
16:614-624.
2014
-
Decongestion in acute heart failure..
16:471-482.
2014
-
The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF Trial..
16:334-341.
2014
-
Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved..
16:33-40.
2014
-
Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties..
16:76-85.
2014
-
Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial..
15:1401-1411.
2013
-
Sex-specific acute heart failure phenotypes and outcomes from PROTECT..
15:1374-1381.
2013
-
Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document..
15:1082-1094.
2013
-
Risk assessment for incident heart failure in individuals with atrial fibrillation..
15:843-849.
2013
-
Heart failure in elderly patients: distinctive features and unresolved issues..
15:717-723.
2013
-
Targeting anti-beta-1-adrenergic receptor antibodies for dilated cardiomyopathy..
15:724-729.
2013
-
Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction..
15:679-689.
2013
-
Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial..
15:551-559.
2013
-
Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF..
15:456-464.
2013
-
Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy..
15:258-266.
2013
-
Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)..
15:334-341.
2013
-
Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation..
15:324-333.
2013
-
Paced QRS duration as a predictor for clinical heart failure events during right ventricular apical pacing in patients with idiopathic complete atrioventricular block: results from an observational cohort study (PREDICT-HF)..
15:352-359.
2013
-
Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial..
15:194-202.
2013
-
Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial..
15:61-68.
2013
-
Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study..
14:1257-1264.
2012
-
Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes..
14:1056-1066.
2012
-
Acute effect of percutaneous MitraClip therapy in patients with haemodynamic decompensation..
14:939-945.
2012
-
Impairment of activities of daily living and incident heart failure in community-dwelling older adults..
14:581-587.
2012
-
The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction..
14:605-612.
2012
-
Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF..
14:395-403.
2012
-
Link between decisions regarding resuscitation and preferences for quality over length of life with heart failure..
14:45-53.
2012
-
Dangerous diuretics or death defying drugs?.
13:1157-1158.
2011
-
Characterization of heart failure patients with preserved ejection fraction: a comparison between ADHERE-US registry and ADHERE-International registry..
13:945-952.
2011
-
Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF..
13:961-967.
2011
-
Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction..
13:148-153.
2011
-
Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function..
12:1238-1246.
2010
-
The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction..
12:1229-1237.
2010
-
Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study..
12:1130-1139.
2010
-
The STICH trial: evidence-based conclusions..
12:1028-1030.
2010
-
Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme..
12:738-745.
2010
-
Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme..
12:557-565.
2010
-
Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study..
12:499-507.
2010
-
Red blood cell distribution width and 1-year mortality in acute heart failure..
12:129-136.
2010
-
Adherence to medication according to sex and age in the CHARM programme..
11:1092-1098.
2009
-
Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial..
11:795-801.
2009
-
Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry.
2020
-
Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF.
2018
-
Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial.
2017
-
Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF.
2015